Literature DB >> 2440390

Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival.

I Norheim, K Oberg, E Theodorsson-Norheim, P G Lindgren, G Lundqvist, A Magnusson, L Wide, E Wilander.   

Abstract

In a prospective study of 103 patients with carcinoid tumors consecutively referred for medical treatment, the most common sites of the primary tumors were the ileum (73%), bronchi (7%), and jejunum (4%). All patients had local metastases, and 96 (93%) also had liver metastases. The most common initial symptoms were diarrhea (32%), ileus (25%), and flush (23%). The overall frequency of diarrhea was 84% and of flush was 75%. Heart insufficiency caused by cardiac valve disease was seen in 33% of the patients. The carcinoid syndrome, including flush, diarrhea, and elevated urinary 5-hydroxyindole acetic acid (5-HIAA) concentrations, was manifested by 69 patients (67%), 64 of whom (93%) had carcinoid tumors of mid-gut origin. Elevated urinary 5-HIAA was found in 91 patients (88%), of which 89 displayed liver metastases. The plasma concentration of the tachykinin neuropeptide K (NPK) was elevated in 67 patients (66%), 63 of whom had tumors of the mid-gut region. Serum pancreatic polypeptide (PP) and human chorionic gonadotrophin alpha levels were elevated in 43% and 28% of the patients, respectively, and the highest levels were found in patients with metastatic bronchial carcinoid tumors. Thirty-nine of the 103 patients are now dead; 18 died of tumor progression, whereas 14 patients died of heart failure secondary to a carcinoid tricuspidal valve insufficiency. The estimated median survival from the time of histologic diagnosis was 14 years, and from the time of carcinoid syndrome was 8 years.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2440390      PMCID: PMC1493111          DOI: 10.1097/00000658-198708000-00001

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  36 in total

1.  A MODIFICATION OF THE MASSON-HAMPERL METHOD FOR STAINING OF ARGENTAFFIN CELLS.

Authors:  I SINGH
Journal:  Anat Anz       Date:  1964-07-31

2.  Case of metastasizing carcinoma (argentaffinoma?) of unknown origin showing peculiar red flushing and increased amounts of histamine and 5-hydroxy-tryptamine in blood and urine.

Authors:  B PERNOW; H SILWER; J WALDENSTROM
Journal:  Acta Med Scand       Date:  1956-12-08

3.  Serum gastrin determination with a radioimmunosorbent technique.

Authors:  G Lundqvist; L Wide
Journal:  Clin Chim Acta       Date:  1977-09-01       Impact factor: 3.786

4.  Prostaglandins in amine-peptide-secreting tumours.

Authors:  M Sandler; S M Karim; E D Williams
Journal:  Lancet       Date:  1968-11-16       Impact factor: 79.321

5.  Serum calcitonin in medullary thyroid carcinoma. Radioimmunoassay technique and diagnostic value.

Authors:  S Almqvist; M Telenius-Berg; B Wästhed
Journal:  Acta Med Scand       Date:  1974-09

6.  Evidence for the release of bradykinin in carcinoid syndrome.

Authors:  J A Oates; W A Pettinger; R B Doctor
Journal:  J Clin Invest       Date:  1966-02       Impact factor: 14.808

7.  Stimulation of connective tissue cell growth by substance P and substance K.

Authors:  J Nilsson; A M von Euler; C J Dalsgaard
Journal:  Nature       Date:  1985 May 2-8       Impact factor: 49.962

8.  Carcinoid tumors.

Authors:  L Dawes; W J Schulte; R E Condon
Journal:  Arch Surg       Date:  1984-04

9.  Carcinoid syndrome from gastrointestinal carcinoids without liver metastasis.

Authors:  J M Feldman; R S Jones
Journal:  Ann Surg       Date:  1982-07       Impact factor: 12.969

10.  Subepithelial neuroendocrine cells and carcinoid tumours of the human small intestine and appendix. A comparative immunohistochemical study with regard to serotonin, neuron-specific enolase and S-100 protein reactivity.

Authors:  M Lundqvist; E Wilander
Journal:  J Pathol       Date:  1986-02       Impact factor: 7.996

View more
  55 in total

1.  Prevalence of Small Intestine Carcinoid Tumors: A US Population-Based Study 2012-2017.

Authors:  Mohannad Abou Saleh; Emad Mansoor; Mohammad Anindo; Gerard Isenberg
Journal:  Dig Dis Sci       Date:  2018-12-05       Impact factor: 3.199

Review 2.  The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.

Authors:  Simon Schimmack; Bernhard Svejda; Benjamin Lawrence; Mark Kidd; Irvin M Modlin
Journal:  Langenbecks Arch Surg       Date:  2011-01-28       Impact factor: 3.445

3.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours.

Authors:  J K Ramage; A H G Davies; J Ardill; N Bax; M Caplin; A Grossman; R Hawkins; A M McNicol; N Reed; R Sutton; R Thakker; S Aylwin; D Breen; K Britton; K Buchanan; P Corrie; A Gillams; V Lewington; D McCance; K Meeran; A Watkinson
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

4.  A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors.

Authors:  J R Strosberg; J M Weber; J Choi; T L Campos; T L Valone; G Han; M J Schell; L K Kvols
Journal:  Ann Oncol       Date:  2012-02-08       Impact factor: 32.976

5.  Carcinoid heart disease with severe hypoxia due to interatrial shunt through patent foramen ovale.

Authors:  L R Boglioli; J Gardiner; G Gerstenblith; M L Taff; D E Cameron
Journal:  Tex Heart Inst J       Date:  1997

Review 6.  Liver transplantation for metastatic neuroendocrine tumor: a case report and review of the literature.

Authors:  Wojciech C Blonski; K Rajender Reddy; Abraham Shaked; Evan Siegelman; David C Metz
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

7.  Four tumours including neuroendocrine tumour of the ileum.

Authors:  Karen Waldon; Jonathan Raihan Abbas; Savana Shakir; Samir Afify
Journal:  BMJ Case Rep       Date:  2015-05-02

Review 8.  Fibrosis and carcinoid syndrome: from causation to future therapy.

Authors:  Maralyn Druce; Andrea Rockall; Ashley B Grossman
Journal:  Nat Rev Endocrinol       Date:  2009-05       Impact factor: 43.330

Review 9.  Biochemical Diagnosis and Preoperative Imaging of Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Jessica E Maxwell; Thomas M O'Dorisio; James R Howe
Journal:  Surg Oncol Clin N Am       Date:  2015-10-31       Impact factor: 3.495

10.  Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors.

Authors:  D Gomez; H Z Malik; A Al-Mukthar; K V Menon; G J Toogood; J P A Lodge; K R Prasad
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.